Brokerages Expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to Post -$1.02 Earnings Per Share

Equities research analysts expect that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will post earnings of ($1.02) per share for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Sarepta Therapeutics’ earnings. The highest EPS estimate is ($0.64) and the lowest is ($1.39). Sarepta Therapeutics posted earnings per share of ($2.40) in the same quarter last year, which suggests a positive year-over-year growth rate of 57.5%. The business is expected to announce its next earnings report on Monday, March 7th.

According to Zacks, analysts expect that Sarepta Therapeutics will report full-year earnings of ($4.99) per share for the current year, with EPS estimates ranging from ($5.29) to ($4.53). For the next year, analysts anticipate that the business will post earnings of ($3.61) per share, with EPS estimates ranging from ($5.10) to ($0.56). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, November 3rd. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.86) by $1.26. Sarepta Therapeutics had a negative return on equity of 86.35% and a negative net margin of 75.30%. The business had revenue of $189.41 million during the quarter, compared to the consensus estimate of $170.13 million. During the same quarter in the prior year, the company posted ($2.50) earnings per share.

Several research firms recently weighed in on SRPT. Cantor Fitzgerald increased their price target on shares of Sarepta Therapeutics from $128.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, November 4th. Needham & Company LLC reduced their price target on shares of Sarepta Therapeutics from $166.00 to $157.00 and set a “buy” rating for the company in a research report on Thursday, November 4th. Credit Suisse Group increased their price target on shares of Sarepta Therapeutics from $75.00 to $100.00 and gave the company a “neutral” rating in a research report on Tuesday, October 12th. JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $88.00 to $130.00 in a report on Friday, November 5th. Finally, SVB Leerink reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, October 12th. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $126.41.

SRPT traded up $1.65 during trading on Friday, hitting $80.98. 415,328 shares of the company traded hands, compared to its average volume of 1,315,641. The firm has a market cap of $7.05 billion, a P/E ratio of -13.23 and a beta of 1.21. The stock’s fifty day moving average is $85.86 and its 200 day moving average is $79.51. The company has a quick ratio of 5.08, a current ratio of 5.85 and a debt-to-equity ratio of 2.33. Sarepta Therapeutics has a one year low of $65.30 and a one year high of $181.83.

In other news, CEO Douglas S. Ingram purchased 25,026 shares of the stock in a transaction dated Wednesday, November 17th. The shares were purchased at an average cost of $79.94 per share, with a total value of $2,000,578.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.90% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC increased its position in shares of Sarepta Therapeutics by 7.3% in the third quarter. Janus Henderson Group PLC now owns 7,398,598 shares of the biotechnology company’s stock worth $684,205,000 after purchasing an additional 503,833 shares during the last quarter. Corient Capital Partners LLC bought a new position in shares of Sarepta Therapeutics in the third quarter worth approximately $237,000. Two Sigma Investments LP increased its position in shares of Sarepta Therapeutics by 1,103.7% in the third quarter. Two Sigma Investments LP now owns 252,376 shares of the biotechnology company’s stock worth $23,340,000 after purchasing an additional 231,409 shares during the last quarter. UBS Group AG increased its position in shares of Sarepta Therapeutics by 37.7% in the third quarter. UBS Group AG now owns 46,731 shares of the biotechnology company’s stock worth $4,322,000 after purchasing an additional 12,796 shares during the last quarter. Finally, LPL Financial LLC increased its position in shares of Sarepta Therapeutics by 21.5% in the third quarter. LPL Financial LLC now owns 31,642 shares of the biotechnology company’s stock worth $2,926,000 after purchasing an additional 5,605 shares during the last quarter. Institutional investors own 78.17% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Featured Story: Bond

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.